Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
Results Reported From Three NCI-Sponsored Clinical Trials SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced results from the analyses of three Phase II clinical trials of ispinesib administered as monotherapy, one in patients with hepatocellular cancer, ...Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
...M, PT, Poster Section 27, Poster Board 14.) ispinesib has been the subject of a broad Phase II clinical ...h the continued development of the KSP inhibitors, ispinesib and SB-743921, subject to GSK's option to resume r... have shown an acceptable tolerability profile for ispinesib in combination with standard chemotherapeutics. Cy...Cytokinetics Announces Interim Clinical Trial Data Relating to ...
Cytokinetics Announces Interim Clinical Trial Data Relating to Ispinesib Presented at the 2008 ASCO Breast Cancer Symposium. - SOUTH SAN FRANCISCO, CA--(MARKET ...Cytokinetics Announces Interim Clinical Trial Data Relating to ...
... ongoing Phase I/II clinical trial of ispinesib were presented in a poster at the ... In that trial, patients received ispinesib as monotherapy at 18 mg/m2 as a 1 ...Cytokinetics Announces the Initiation of a Phase I/II Clinical Trial ...
... label, non-randomized Phase I/II clinical trial designed to evaluate ispinesib ... Ispinesib will be administered as a 1-hour intravenous infusion on days ...News: Cytokinetics Announces Clinical Data Regarding Ispinesib in ...
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the results of a Phase Ib clinical trial designed to evaluate ispinesib in combination with capecitabine, ...News: Cytokinetics Announces Clinical and Preclinical Data Regarding ...
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two posters, one summarizing interim Phase I clinical trial data evaluating ispinesib in the treatment ...